Ticker BIAF
My interview with Maria Zannes, the President and Chief Executive Officer of bioAffinity Technologies, is one of the most important conversations I have had with a leader in the medical diagnostics space. Maria is direct, experienced, and focused. What impressed me most is that everything she discussed is already happening. This is not a company speaking about the future. This is a company operating right now with real revenue and real adoption.
During the interview, Maria walked me through how their CyPath Lung test is already being used in multiple clinics and small hospital systems in Texas. They are already expanding into other states and the demand is growing as more physicians learn about the technology. She made it clear that this product is not waiting on approval or future validation. Clinics are ordering it today and patients are benefiting from it today.
We talked about the company’s financial growth, which has been remarkable. bioAffinity went from 2.3 million in revenue in 2023 to 9.36 million in 2024. They have already generated 1.8 million so far this year. These numbers tell the story of a company moving from early stage to real commercial traction. Maria explained how they reached this level of growth and what they expect over the next twelve to twenty four months as more states and more health systems join.
She also broke down the 111 percent increase in test volume for 2025, which is one of the clearest signs that doctors are using this test and trusting it in real clinical settings. This level of growth does not happen by accident. It happens when a product solves a real problem. CyPath Lung helps detect lung cancer earlier, which gives doctors more clarity and reduces unnecessary biopsies and risky procedures. Maria talked about the importance of early detection in lung cancer and why this test matters for both patients and physicians.
Maria also shared that bioAffinity is not a one product company. They are building additional diagnostics based on the same technology platform. This gives long term investors exposure to a larger pipeline and future revenue streams. She walked me through the upcoming products and how they plan to expand their presence across the country through strategic partnerships and continued clinical adoption.
What stood out to me is that Maria is running this company with discipline. They are focused on reducing debt, managing expenses properly, and scaling the right way. Many early biotech companies struggle because they burn money without results. Maria is doing the opposite. She is growing revenue while tightening operations, which is uncommon and very important for long term investors.
Maria also shared her long term vision for the company. She sees bioAffinity becoming a nationwide leader in early detection diagnostics with a full suite of products. She laid out a clear plan for how they intend to grow, what states they are targeting next, and how they will build more clinical relationships. Her vision is grounded in data, execution, and real world adoption.
If you follow Marathon Money, you know that I highlight companies that show real traction and real leadership. Maria Zannes delivered both. With a float under 30 million shares and revenue already accelerating, this is a company that can move fast the moment more investors start paying attention.
My full interview with Maria goes live Monday the 24th. This is one of those conversations you watch the moment it drops. It will give you the full story behind the company, the product, the growth, and the long term opportunity. If you want, I can now write your YouTube title, YouTube description, thumbnail lines, or a promo post for MarathonMoneyPlus.com.
Podcast: Play in new window | Download
Discover more from Marathon Money +
Subscribe to get the latest posts sent to your email.